Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Abstracts are published as soon as they are released and are open access.
Slides and webcasts are published the morning after the session and are restricted to attendees and ESMO Members.
ePoster are published the morning after the end of the meeting and are open to all with at least a free ESMO account.
Please note that resources are available according the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Slides and webcasts are restricted to attendees and ESMO Members.
Abstracts are open access.
ePosters are open to all with at least a free ESMO account.
Twice daily poziotinib dosing improved the adverse event profile; early results showed retained anti-tumour activity
Clinical benefit of FGFR inhibition is stronger in patients with an FGFR fusion or mutation compared to FGFR amplification
Prelliminary data with IL-12 mRNA administered by intratumoural injection in combination with intravenous durvalumab
Overall, more adverse events were reported with targeted therapies than with immunotherapy.
Many cancer patients with autoimmune disease are excluded from studies of immune checkpoint inhibitors due to hypothesis of the association of this treatment with immune-related adverse events
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
